Global Active Pharmaceutical Ingredients (APIs) Market to reach USD 264.1 Billion by 2027 at a CAGR of 6%

DUBLIN, November 2, 2022 /PRNewswire/ — The “Active Pharmaceutical Ingredients (APIs) – Global Market Trajectory and Analysis” report has been added to from ResearchAndMarkets.com offer.

Global Active Pharmaceutical Ingredients (API) Market to Reach $264.1 billion by 2027

Amid the COVID-19 crisis, the global Active Pharmaceutical Ingredients (APIs) market estimated at US$176.1 billion in 2020, is expected to reach a revised size of US$264.1 billion by 2027, growing at a CAGR of 6% over the period 2020-2027. Innovative, one of the segments analyzed in the report, is expected to register a CAGR of 5.7% and reach US$180.5 billion at the end of the analysis period. Given the ongoing post-pandemic recovery, generics segment growth is readjusted to a revised CAGR of 6.6% for the next 7-year period.

The US market is estimated at $61 billionWhile China is expected to grow at a CAGR of 6.2%

The Active Pharmaceutical Ingredients (APIs) Market in the United States is estimated at US$61 billion in the year 2020. Chinathe second largest economy in the world, is expected to reach a projected market size of 42 billion US dollars by 2027 growing at a CAGR of 6.2% over the period 2020 to 2027. Other notable geographic markets include Japan and Canada, each expected to grow by 5.3% and 5.6% respectively over the 2020-2027 period. In Europe, Germany is expected to grow at around 5.4% CAGR.

Select contestants (266 total featured)

  • AbbVie Inc.
  • Aurobindo Pharma Ltd.
  • BASF SE
  • Boehringer Ingelheim International GmbH
  • cipla ltd.
  • Dr. Reddy’s Laboratories Ltd.
  • Lupine Ltd.
  • Merck KGaA
  • Novartis International AG
  • Pfizer Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Viatris inc.

Main topics covered:

I. METHODOLOGY

II. ABSTRACT

1. MARKET OVERVIEW

2. FOCUS ON CERTAIN PLAYERS

3. MARKET TRENDS AND DRIVERS

  • Sustained Increase in Drug R&D Spending to Drive API Market
  • Increase in API Supply Creates Need for Greater Vendor Screening for Higher Quality Products
  • Growing preference for specialist CDMO contractors
  • Strong increase in sales of pharmaceutical products to stimulate demand
  • The AIC approach for faster evaluation of viable drug candidates
  • Drugmakers are embracing digital technology amid the COVID-19 crisis
  • HPAPI demand on the rise
  • AI is finding increasing application in drug discovery and development
  • Beneficial microdosing for the formulation of high potency ingredients
  • Rising penetration of generic drugs increases market prospects
  • Growing Interest in Biopharmaceuticals Supports Market Demand
  • Growing number of organic product approvals bodes well
  • Growing Biosimilars Market Creates Opportunities for APIs
  • Growing focus on personalized medicine is driving demand for complex APIs
  • Rising sales of over-the-counter drugs present an opportunity for APIs
  • Growing prevalence of infectious diseases to drive growth
  • Increase in cancer incidence and the need to reduce cancer-related mortality
  • Rising prevalence of chronic disorders is fueling market growth
  • Rising incidence of cardiovascular disease increases opportunities
  • The upsurge in ANDA approvals bodes well
  • Aging population and increasing burden of chronic diseases drive pharmaceutical sales and drive market growth
  • New technology for continuous API manufacturing

4. GLOBAL MARKET OUTLOOK

III. MARKET ANALYSIS

IV. COMPETITION

  • Total number of companies profiled: 266

For more information on this report, visit https://www.researchandmarkets.com/r/jmlnn1

Media Contact:

Research and Markets
Laura Woodsenior
[email protected]

For EST office hours, call +1-917-300-0470
For USA/CAN call toll free +1-800-526-8630
For GMT office hours call +353-1-416-8900

US Fax: 646-607-1907
Fax (outside the US): +353-1-481-1716

Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

SOURCE Research and Markets